<SUBMISSION>
<ACCESSION-NUMBER>0001144204-07-046869
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20070827
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20070829
<DATE-OF-FILING-DATE-CHANGE>20070829
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NEKTAR THERAPEUTICS
<CIK>0000906709
<ASSIGNED-SIC>2834
<IRS-NUMBER>943134940
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-24006
<FILM-NUMBER>071085414
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>150 INDUSTRIAL RD
<CITY>SAN CARLOS
<STATE>CA
<ZIP>94070
<PHONE>6506313100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>150 INDUSTRIAL ROAD
<CITY>SAN CARLOS
<STATE>CA
<ZIP>94070
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>INHALE THERAPEUTIC SYSTEMS INC
<DATE-CHANGED>19980723
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>INHALE THERAPEUTIC SYSTEMS
<DATE-CHANGED>19940303
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v086514_8k.txt
<TEXT>

--------------------------------------------------------------------------------

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): August 27, 2007

                               NEKTAR THERAPEUTICS
             (Exact name of Registrant as specified in its charter)

          Delaware                   0-24006                  94-3134940
(State or other jurisdiction       (Commission              (IRS Employer
      of incorporation)            File Number)          Identification No.)

                               201 Industrial Road
                          San Carlos, California 94070
              (Address of principal executive offices and Zip Code)

       Registrant's telephone number, including area code: (650) 631-3100

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

--------------------------------------------------------------------------------

<PAGE>

Item 5.02  Departure of Directors or Certain  Officers;  Election of  Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

      On August 27, 2007,  the Board of Directors  of Nektar  Therapeutics  (the
"Company")  appointed  Mr.  Lutz  Lingnau as a new  director to fill the vacancy
created by  resolution  of the Board of  Directors  to increase  the  authorized
number of directors  from 9 to 10. Mr.  Lingnau will serve until the 2010 annual
meeting of stockholders or until his successor is duly elected and qualified. On
August 29, 2007, the Company issued a press release  announcing the  appointment
of Mr. Lingnau, a copy of which is included as Exhibit 99.1 to this filing.

      Mr. Lingnau, age 64, retired from Schering AG Group, Germany, in 2005 as a
member of Schering  AG's  Executive  Board and as Vice  Chairman,  President and
Chief Executive  Officer of Schering Berlin,  Inc., a United States  subsidiary.
Prior to his retirement, Mr. Lingnau was responsible for Schering AG's worldwide
specialized  therapeutics  and dermatology  businesses.  He joined Schering AG's
business  trainee  program in 1966.  Throughout  his career at  Schering  AG, he
served in various  capacities and in a number of  subsidiaries  in South America
and the United States,  including his roles as President of Berlex Laboratories,
Inc.,  from 1983 to 1985,  as the Head of Worldwide  Sales and  Marketing in the
Pharmaceutical  Division of Schering  AG, from 1985 to 1989,  and as Chairman of
Berlex  Laboratories,  Inc. from 1985 to 2005. Mr. Lingnau is currently a member
of the  Supervisory  Board of LANXESS AG,  Chairman of the Board of Directors of
Micropharma  Limited, a biotechnology  company, and was a member of the Board of
Directors of Sirna Therapeutics,  Inc., a biotechnology  company,  from February
2006  through the closing of the  acquisition  of Sirna by Merck & Co.,  Inc. in
December 2006.

      There are no  arrangements or  understandings  between Mr. Lingnau and any
other persons pursuant to which he was selected as a director.  Mr. Lingnau will
participate  in  the  Company's  Amended  and  Restated  Compensation  Plan  for
Non-Employee  Directors  filed by the  Company  on  February  23,  2007 with the
Securities and Exchange  Commission on a Current Report on Form 8-K. Mr. Lingnau
is not a party to any transaction with the Company that would require disclosure
under Item 404(a) of Securities and Exchange Commission's Regulation S-K.


Item 9.01  Financial Statements and Exhibits.

(d) Exhibits:

--------------------------------------------------------------------------------
Exhibit
No.           Description
--------------------------------------------------------------------------------

99.1          Press release titled "Nektar Therapeutics Appoints Lutz Lingnau as
              New Board Member."

--------------------------------------------------------------------------------

<PAGE>

                                   SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                        By: /s/ Gil M. Labrucherie
                                            -----------------------------------
                                                Gil M. Labrucherie
                                                Senior Vice President, General
                                                Counsel and Secretary

                                        Date:   August 29, 2007
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v086514_ex99-1.txt
<TEXT>


                                                                          NEKTAR
--------------------------------------------------------------------------------
News Release

Necktar Therapeutics          150 Industrial Road                 San Carlos, CA
650-631-3100 Phone              650-631-3150 Fax                  www.nektar.com
--------------------------------------------------------------------------------


          Nektar Therapeutics Appoints Lutz Lingnau as New Board Member

San Carlos, Calif., August 29, 2007 --- Nektar Therapeutics (Nasdaq: NKTR)
announced today that Mr. Lutz Lingnau has been appointed to serve on its board
of directors. Lingnau is a highly-respected pharmaceutical industry leader with
over 35 years of experience in corporate management, product development and
marketing.

"Lutz Lingnau brings to Nektar extensive pharmaceutical development and
commercialization experience at an important point in the company's evolution,"
said Howard W. Robin, President and CEO of Nektar. "As we continue to drive our
proprietary programs through the clinic, it is imperative that we leverage the
strategic guidance of leaders like Lutz who have a proven track record of
bringing successful therapeutics to market."

Most recently, Lingnau was a member of the Executive Board at Schering AG and
Vice Chairman, President and CEO of Schering Berlin, Inc. While at Schering AG,
he was responsible for the worldwide specialized therapeutics business and also
held a number of other executive positions including Head of Worldwide Sales and
Marketing in the Pharmaceutical Division, and Chairman and President of Berlex
Laboratories, Inc.


"Nektar's innovative development of therapeutics using its proprietary
PEGylation and pulmonary technologies is among the most important areas in
biopharmaceutical drug development," Lingnau said. "I look forward to working
with Howard and his executive team as they move Nektar's clinical pipeline
forward and advance the company's strategic business objectives."

Lingnau is also currently a member of the Supervisory Board of LANXESS AG,
Germany and Chairman of the Board of Directors of Micropharma Ltd., Montreal. He
was formerly a member of the Board of Directors of Sirna Therapeutics, which was
acquired by Merck & Co., Inc. in December 2006.


<PAGE>

About Nektar

Nektar Therapeutics is a biopharmaceutical company with a mission to develop and
enable differentiated therapeutics with its industry-leading pulmonary and
PEGylation technology platforms. Nektar pulmonary and PEGylation technology,
expertise, manufacturing capabilities and know-how have enabled nine approved
products for partners, which include the world's leading pharmaceutical and
biotechnology companies. Nektar also develops its own products by applying its
pulmonary and PEGylation technology platforms to existing medicines with the
objective to enhance performance, such as improving efficacy, safety and
compliance.

This press release contains forward-looking statements that reflect the
company's current views as to its management team, board of directors, revenue
potential, product pipeline potential and business prospects. These forward-
looking statements involve risks and uncertainties, including but not limited
to: (i) the company's proprietary product candidates and those of certain of its
partners are in the early phases of clinical development and the risk of failure
is high and can occur at any stage prior to regulatory approval, (ii) the
company's or its partner's ability to obtain regulatory approval for product
candidates, (iii) the success of the company's partners in sales and marketing
efforts to generate from approved products and future products (if any), and
(iv) the company's patent applications for its technology platforms and
proprietary or partner product candidates may not issue, patents that have
issued may not be enforceable, or intellectual property licenses from third
parties may be required in the future. Important risks and uncertainties are
detailed in the company's reports and other filings with the Securities and
Exchange Commission, including its most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q. Actual results could differ materially from the
forward-looking statements contained in this press release. The company
undertakes no obligation to update forward-looking statements, whether as a
result of new information, future events or otherwise.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com (investors)

Stephan Herrera (415) 488-7699 or sherrera@nektar.com (investors)

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com (media)



                                      # # #

</TEXT>
</DOCUMENT>
</SUBMISSION>
